Cargando…
Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma
Hodgkin lymphoma (HL) represents ~11% of all lymphoma cases. This disease occurs in young adults, but also affects people over 55 years of age. Despite the fact that >80% of all newly diagnosed patients under 60 will achieve a sustained complete response (CR), 5%–10% of HL patients are refractory...
Autores principales: | Garcia-Recio, Marta, Martinez-Serra, Jordi, Mestre, Francesc, Bento, Leyre, Gines, Jordi, Ramos, Rafael, Daumal, Jaime, López, Paloma, Sampol, Antonia, Gutierrez, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188182/ https://www.ncbi.nlm.nih.gov/pubmed/30349293 http://dx.doi.org/10.2147/OTT.S175016 |
Ejemplares similares
-
Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report
por: Garcia-Recio, Marta, et al.
Publicado: (2016) -
Total Lesion Glycolysis Improves Tumor Burden Evaluation and Risk Assessment at Diagnosis in Hodgkin Lymphoma
por: Herraez, Ines, et al.
Publicado: (2021) -
Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
por: Gutierrez, Antonio, et al.
Publicado: (2014) -
Prognostic Role of the Red Blood Cell Distribution Width (RDW) in Hodgkin Lymphoma
por: Herraez, Ines, et al.
Publicado: (2020) -
Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019)